Inovio Pharmaceuticals (INO) Target Priced Lifted to $4 at Brean Capital
Tweet Send to a Friend
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and raised his price target on Inovio Pharmaceuticals (NYSE: INO) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE